{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:45:27Z","timestamp":1780735527456,"version":"3.54.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1T32HL098069-01A1"],"award-info":[{"award-number":["1T32HL098069-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1T32HL098069-01A1"],"award-info":[{"award-number":["1T32HL098069-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1T32HL098069-01A1"],"award-info":[{"award-number":["1T32HL098069-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02197-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:48:57Z","timestamp":1740545337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes"],"prefix":"10.1007","volume":"27","author":[{"given":"Fatema Tuj","family":"Zohora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Sinusas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"20","key":"2197_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","volume":"55","author":"AF Jacobson","year":"2010","unstructured":"Jacobson AF, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2197_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jacc.2013.07.096","volume":"63","author":"JA Fallavollita","year":"2014","unstructured":"Fallavollita JA, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63(2):141\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2197_CR3","first-page":"1036","volume":"13","author":"JG Zelt","year":"2020","unstructured":"Zelt JG, et al. Nuclear imaging of the cardiac sympathetic nervous system: a disease-specific interpretation in heart failure. Cardiovasc Imaging. 2020;13(4):1036\u201354.","journal-title":"Cardiovasc Imaging"},{"issue":"Supplement 4","key":"2197_CR4","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.114.142794","volume":"56","author":"K Nakajima","year":"2015","unstructured":"Nakajima K, Nakata T. Cardiac 123I-MIBG imaging for clinical decision making: 22-year experience in Japan. J Nucl Med. 2015;56(Supplement 4):11S-19S.","journal-title":"J Nucl Med"},{"key":"2197_CR5","first-page":"1349","volume-title":"Heart disease: a textbook of cardiovascular medicine","author":"JAC Goldberger","year":"2022","unstructured":"Goldberger JAC, Myerburg R. Cardiac arrest and sudden cardiac death. In: Heart disease: a textbook of cardiovascular medicine. Philadelphia: Elsevier; 2022. p. 1349\u201386."},{"issue":"20","key":"2197_CR6","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1161\/01.CIR.103.20.2447","volume":"103","author":"PM Spooner","year":"2001","unstructured":"Spooner PM, et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, part II. Circulation. 2001;103(20):2447\u201352.","journal-title":"Circulation"},{"issue":"2","key":"2197_CR7","first-page":"212","volume":"7","author":"EC Stecker","year":"2014","unstructured":"Stecker EC, et al. Public health burden of sudden cardiac death in the United States. Circulation: Arrhythmia Electrophysiol. 2014;7(2):212\u20137.","journal-title":"Circulation: Arrhythmia Electrophysiol"},{"issue":"12","key":"2197_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1161\/CIRCRESAHA.116.304521","volume":"116","author":"M Hayashi","year":"2015","unstructured":"Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015;116(12):1887\u2013906.","journal-title":"Circ Res"},{"issue":"18","key":"2197_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/eurheartj\/ehz553","volume":"41","author":"M Packer","year":"2020","unstructured":"Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757\u201363.","journal-title":"Eur Heart J"},{"issue":"6","key":"2197_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S0735-1097(97)00355-0","volume":"30","author":"JJ de Vreede-Swagemakers","year":"1997","unstructured":"de Vreede-Swagemakers JJ, et al. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30(6):1500\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1001\/jama.1983.03340200048027","volume":"250","author":"I Morbidity","year":"1983","unstructured":"Morbidity I. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1983;250:2814\u20139.","journal-title":"JAMA"},{"issue":"3","key":"2197_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/01.CIR.73.3.503","volume":"73","author":"K Chadda","year":"1986","unstructured":"Chadda K, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73(3):503\u201310.","journal-title":"Circulation"},{"issue":"5","key":"2197_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.7326\/0003-4819-123-5-199509010-00007","volume":"123","author":"MJ Kendall","year":"1995","unstructured":"Kendall MJ, et al. \u03b2-Blockers and sudden cardiac death. Ann Intern Med. 1995;123(5):358\u201367.","journal-title":"Ann Intern Med"},{"issue":"17","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1161\/01.CIR.99.17.2268","volume":"99","author":"F Boutitie","year":"1999","unstructured":"Boutitie F, et al. Amiodarone interaction with \u03b2-blockers: Analysis of the merged EMIAT (European myocardial infarct amiodarone trial) and CAMIAT (Canadian amiodarone myocardial infarction trial) databases. Circulation. 1999;99(17):2268\u201375.","journal-title":"Circulation"},{"issue":"7","key":"2197_CR15","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/01.CIR.60.7.1430","volume":"60","author":"ME Josephson","year":"1979","unstructured":"Josephson ME, Harken AH, Horowitz LN. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation. 1979;60(7):1430\u20139.","journal-title":"Circulation"},{"issue":"2","key":"2197_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0002-8703(81)80017-8","volume":"102","author":"M Mirowski","year":"1981","unstructured":"Mirowski M, et al. Clinical treatment of life-threatening ventricular tachyarrhythmias with the automatic implantable defibrillator. Am Heart J. 1981;102(2):265\u201370.","journal-title":"Am Heart J"},{"issue":"12","key":"2197_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877\u201383.","journal-title":"N Engl J Med"},{"issue":"25","key":"2197_CR18","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1161\/01.CIR.0000150390.04704.B7","volume":"110","author":"AJ Moss","year":"2004","unstructured":"Moss AJ, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760\u20135.","journal-title":"Circulation"},{"issue":"10","key":"2197_CR19","first-page":"2223","volume":"13","author":"C Gr\u00e4ni","year":"2020","unstructured":"Gr\u00e4ni C, et al. Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies. Cardiovasc Imaging. 2020;13(10):2223\u201338.","journal-title":"Cardiovasc Imaging"},{"issue":"24","key":"2197_CR20","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1161\/CIRCULATIONAHA.111.023879","volume":"125","author":"R Passman","year":"2012","unstructured":"Passman R, Goldberger JJ. Predicting the future: risk stratification for sudden cardiac death in patients with left ventricular dysfunction. Circulation. 2012;125(24):3031\u20137.","journal-title":"Circulation"},{"issue":"3","key":"2197_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, et al. Amiodarone or an implantable cardioverter\u2013defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225\u201337.","journal-title":"N Engl J Med"},{"issue":"7","key":"2197_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/clc.4960220709","volume":"22","author":"AJ Camm","year":"1999","unstructured":"Camm AJ, et al. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22(7):481\u20139.","journal-title":"Clin Cardiol"},{"issue":"1","key":"2197_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2190\/1G9V-EQMD-MTLQ-E0BW","volume":"27","author":"MT Hegel","year":"1997","unstructured":"Hegel MT, et al. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med. 1997;27(1):57\u201369.","journal-title":"Int J Psychiatry Med"},{"issue":"4","key":"2197_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0147-9563(05)80071-8","volume":"24","author":"CM Dougherty","year":"1995","unstructured":"Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung. 1995;24(4):281\u201391.","journal-title":"Heart Lung"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijcard.2017.08.003","volume":"248","author":"DO Verschure","year":"2017","unstructured":"Verschure DO, et al. Cardiac 123I-mIBG scintigraphy is associated with freedom of appropriate ICD therapy in stable chronic heart failure patients. Int J Cardiol. 2017;248:403\u20138.","journal-title":"Int J Cardiol"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-017-0817-2","volume":"19","author":"MI Travin","year":"2017","unstructured":"Travin MI. Current clinical applications and next steps for cardiac innervation imaging. Curr Cardiol Rep. 2017;19:1\u201311.","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"2197_CR27","first-page":"1070","volume":"15","author":"C Pacing","year":"2013","unstructured":"Pacing C. ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2013;15(8):1070\u2013118.","journal-title":"Eur Heart J"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40336-018-0289-4","volume":"6","author":"RA Werner","year":"2018","unstructured":"Werner RA, et al. SPECT vs. PET in cardiac innervation imaging: clash of the titans. Clin Trans Imaging. 2018;6:293\u2013303.","journal-title":"Clin Trans Imaging"},{"issue":"1","key":"2197_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41181-023-00203-5","volume":"8","author":"LY Haveman","year":"2023","unstructured":"Haveman LY, Vugts DJ, Windhorst AD. State of the art procedures towards reactive [18F] fluoride in PET tracer synthesis. EJNMMI Radiopharm Chem. 2023;8(1):28.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"2197_CR30","first-page":"273","volume":"2","author":"DD Nolting","year":"2012","unstructured":"Nolting DD, et al. Molecular imaging probe development: a chemistry perspective. Am J Nuclear Med Mole Imaging. 2012;2(3):273.","journal-title":"Am J Nuclear Med Mole Imaging"},{"issue":"6","key":"2197_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.bmcl.2013.01.106","volume":"23","author":"KS Jang","year":"2013","unstructured":"Jang KS, et al. Synthesis and bioevaluation of [18F] 4-fluoro-m-hydroxyphenethylguanidine ([18F] 4F-MHPG): a novel radiotracer for quantitative PET studies of cardiac sympathetic innervation. Bioorg Med Chem Lett. 2013;23(6):1612\u20136.","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"2197_CR32","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s12350-021-02813-5","volume":"29","author":"M Grkovski","year":"2022","unstructured":"Grkovski M, et al. F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. J Nucl Cardiol. 2022;29(6):3179\u201388.","journal-title":"J Nucl Cardiol"},{"issue":"12","key":"2197_CR33","first-page":"2011","volume":"37","author":"CR Berry","year":"1996","unstructured":"Berry CR, et al. Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart. J Nucl Med. 1996;37(12):2011\u20136.","journal-title":"J Nucl Med"},{"issue":"9","key":"2197_CR34","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.7150\/thno.63205","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Molecular Imaging-Derived Biomarker of Cardiac Nerve Integrity\u2014Introducing High NET Affinity PET Probe 18F-AF78. Theranostics. 2022;12(9):4446.","journal-title":"Theranostics"},{"issue":"2","key":"2197_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/pharmaceutics15020690","volume":"15","author":"A Tutov","year":"2023","unstructured":"Tutov A, et al. Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter. Pharmaceutics. 2023;15(2):690.","journal-title":"Pharmaceutics"},{"key":"2197_CR36","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Pekker MJ, Eisenhofer G, Sharabi Y. Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCI Insight. 2019;4(16):e130441.","DOI":"10.1172\/jci.insight.130441"},{"issue":"7","key":"2197_CR37","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/0735-1097(93)90786-Z","volume":"22","author":"DS Goldstein","year":"1993","unstructured":"Goldstein DS, et al. Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F] fluorodopamine: initial findings in humans. J Am Coll Cardiol. 1993;22(7):1961\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2197_CR38","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1021\/acschemneuro.1c00575","volume":"12","author":"US Ismailani","year":"2021","unstructured":"Ismailani US, et al. Cardiac Sympathetic Positron Emission Tomography Imaging with Meta-[18F] Fluorobenzylguanidine is Sensitive to Uptake-1 in Rats. ACS Chem Neurosci. 2021;12(22):4350\u201360.","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"2197_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s11307-023-01844-3","volume":"25","author":"L Yang","year":"2023","unstructured":"Yang L, et al. Preliminary Evaluation of 18F-Labeled Benzylguanidine Analogs as NET Tracers for Myocardial Infarction Diagnosis. Mol Imag Biol. 2023;25(6):1125\u201334.","journal-title":"Mol Imag Biol"},{"key":"2197_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF02267622","volume":"7","author":"D Goldstein","year":"1997","unstructured":"Goldstein D, et al. 6-[18 F] Fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function\u2014studies in normal humans. Clin Auton Res. 1997;7:17\u201329.","journal-title":"Clin Auton Res"},{"issue":"4","key":"2197_CR41","first-page":"435","volume":"4","author":"M Yu","year":"2011","unstructured":"Yu M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circulation: Cardiovasc Imaging. 2011;4(4):435\u201343.","journal-title":"Circulation: Cardiovasc Imaging"},{"issue":"8","key":"2197_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2967\/jnumed.110.084228","volume":"52","author":"FM Bengel","year":"2011","unstructured":"Bengel FM. Imaging targets of the sympathetic nervous system of the heart: translational considerations. J Nucl Med. 2011;52(8):1167\u201370.","journal-title":"J Nucl Med"},{"issue":"1","key":"2197_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0006-8993(00)02649-4","volume":"877","author":"OT DeJesus","year":"2000","unstructured":"DeJesus OT, et al. 6-fluoroDOPA metabolism in rat striatum: time course of extracellular metabolites. Brain Res. 2000;877(1):31\u20136.","journal-title":"Brain Res"},{"issue":"1","key":"2197_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0969-8051(97)00158-3","volume":"25","author":"TR DeGrado","year":"1998","unstructured":"DeGrado TR, et al. Effects of specific activity on meta-[131I] iodobenzylguanidine kinetics in isolated rat heart. Nucl Med Biol. 1998;25(1):59\u201364.","journal-title":"Nucl Med Biol"},{"issue":"8","key":"2197_CR45","first-page":"1287","volume":"34","author":"TR DeGrado","year":"1993","unstructured":"DeGrado TR, et al. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med. 1993;34(8):1287\u201393.","journal-title":"J Nucl Med"},{"issue":"5","key":"2197_CR46","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/01.CIR.101.5.516","volume":"101","author":"GT M\u00fcnch","year":"2000","unstructured":"M\u00fcnch GT, et al. Evaluation of sympathetic nerve terminals with [11C] epinephrine and [11C] hydroxyephedrine and positron emission tomography. Circulation. 2000;101(5):516\u201323.","journal-title":"Circulation"},{"key":"2197_CR47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00259-007-0668-y","volume":"35","author":"HJ Verberne","year":"2008","unstructured":"Verberne HJ, et al. Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123 I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imaging. 2008;35:798\u2013807.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2197_CR48","first-page":"129","volume":"22","author":"RC Kline","year":"1981","unstructured":"Kline RC, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22(2):129\u201332.","journal-title":"J Nucl Med"},{"issue":"4","key":"2197_CR49","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/mdc3.13190","volume":"8","author":"A Lenka","year":"2021","unstructured":"Lenka A, Lamotte G, Goldstein DS. Cardiac 18F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA. Movement Disorders Clinical Practice. 2021;8(4):582\u20136.","journal-title":"Movement Disorders Clinical Practice"},{"key":"2197_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-015-0613-9","volume":"17","author":"S Malhotra","year":"2015","unstructured":"Malhotra S, et al. Prognostic significance of imaging myocardial sympathetic innervation. Curr Cardiol Rep. 2015;17:1\u201310.","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"2197_CR51","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/01.CIR.93.9.1667","volume":"93","author":"G Eisenhofer","year":"1996","unstructured":"Eisenhofer G, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93(9):1667\u201376.","journal-title":"Circulation"},{"key":"2197_CR52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2165\/00002018-200730110-00004","volume":"30","author":"G Eisenhofer","year":"2007","unstructured":"Eisenhofer G, et al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf. 2007;30:1031\u201362.","journal-title":"Drug Saf"},{"key":"2197_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-017-0843-0","volume":"19","author":"NE Boutagy","year":"2017","unstructured":"Boutagy NE, Sinusas AJ. Recent advances and clinical applications of PET cardiac autonomic nervous system imaging. Curr Cardiol Rep. 2017;19:1\u201313.","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"2197_CR54","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1006\/jmcc.2000.1319","volume":"33","author":"J Backs","year":"2001","unstructured":"Backs J, et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol. 2001;33(3):461\u201372.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"2197_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0002-9149(97)00345-7","volume":"80","author":"J Hartikainen","year":"1997","unstructured":"Hartikainen J, et al. Cardiac sympathetic denervation in patients with coronary artery disease without previous myocardial infarction. Am J Cardiol. 1997;80(3):273\u20137.","journal-title":"Am J Cardiol"},{"issue":"suppl_D","key":"2197_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/eurheartj\/12.suppl_D.171","volume":"12","author":"V Regitz","year":"1991","unstructured":"Regitz V, et al. Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur Heart J. 1991;12(suppl_D):171\u20134.","journal-title":"Eur Heart J"},{"issue":"19","key":"2197_CR57","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, et al. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2197_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/01.HYP.29.1.137","volume":"29","author":"MJ Morris","year":"1997","unstructured":"Morris MJ, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997;29(1):137\u201343.","journal-title":"Hypertension"},{"issue":"2","key":"2197_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","volume":"53","author":"G Grassi","year":"2009","unstructured":"Grassi G, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53(2):205\u20139.","journal-title":"Hypertension"},{"issue":"10","key":"2197_CR60","first-page":"1625","volume":"28","author":"J Sisson","year":"1987","unstructured":"Sisson J, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28(10):1625\u201336.","journal-title":"J Nucl Med"},{"issue":"9","key":"2197_CR61","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehn113","volume":"29","author":"HJ Verberne","year":"2008","unstructured":"Verberne HJ, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29(9):1147\u201359.","journal-title":"Eur Heart J"},{"issue":"5","key":"2197_CR62","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jacc.2008.10.025","volume":"53","author":"S Tamaki","year":"2009","unstructured":"Tamaki S, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53(5):426\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2197_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12350-008-9008-2","volume":"16","author":"AF Jacobson","year":"2009","unstructured":"Jacobson AF, et al. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16(1):113\u201321.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2197_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jacc.2020.04.080","volume":"76","author":"MA Nazari","year":"2020","unstructured":"Nazari MA, et al. Pathophysiology and acute management of tachyarrhythmias in pheochromocytoma: JACC review topic of the week. J Am Coll Cardiol. 2020;76(4):451\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2197_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnmt.115.158394","volume":"43","author":"SS Van Vickle","year":"2015","unstructured":"Van Vickle SS, Thompson RC. 123I-MIBG imaging: patient preparation and technologist\u2019s role. J Nucl Med Technol. 2015;43(2):82\u20136.","journal-title":"J Nucl Med Technol"},{"key":"2197_CR66","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","volume":"23","author":"MJ Henzlova","year":"2016","unstructured":"Henzlova MJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23:606\u201339.","journal-title":"J Nucl Cardiol"},{"issue":"12","key":"2197_CR67","first-page":"e003110","volume":"8","author":"R Hachamovitch","year":"2015","unstructured":"Hachamovitch R, et al. Predicting risk versus predicting potential survival benefit using 123I-m IBG imaging in patients with systolic dysfunction eligible for implantable cardiac defibrillator implantation analysis of data from the prospective ADMIRE-HF Study. Circ: Cardiovasc Imaging. 2015;8(12):e003110.","journal-title":"Circ: Cardiovasc Imaging"},{"issue":"4","key":"2197_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/0735-1097(94)00463-Z","volume":"25","author":"T De Marco","year":"1995","unstructured":"De Marco T, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol. 1995;25(4):927\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2197_CR69","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1253\/circj.CJ-17-0817","volume":"82","author":"M Sobajima","year":"2018","unstructured":"Sobajima M, et al. Transcatheter aortic valve implantation improves cardiac sympathetic nerve activity on 123I-metaiodobenzylguanidine myocardial scintigraphy in severe aortic valve stenosis. Circ J. 2018;82(2):579\u201385.","journal-title":"Circ J"},{"issue":"2","key":"2197_CR70","first-page":"87","volume":"4","author":"MC Gerson","year":"2011","unstructured":"Gerson MC, et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circulation: Cardiovasc Imaging. 2011;4(2):87\u201393.","journal-title":"Circulation: Cardiovasc Imaging"},{"issue":"12","key":"2197_CR71","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1253\/circj.CJ-16-0690","volume":"80","author":"S Yamamoto","year":"2016","unstructured":"Yamamoto S, et al. Focal reduction in cardiac 123I-metaiodobenzylguanidine uptake in patients with anderson-Fabry disease. Circ J. 2016;80(12):2550\u20131.","journal-title":"Circ J"},{"issue":"12","key":"2197_CR72","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1212\/01.wnl.0000219640.59984.a7","volume":"66","author":"M Yoshita","year":"2006","unstructured":"Yoshita M, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66(12):1850\u20134.","journal-title":"Neurology"},{"issue":"9","key":"2197_CR73","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2967\/jnumed.115.158493","volume":"56","author":"RA Werner","year":"2015","unstructured":"Werner RA, et al. Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG. J Nucl Med. 2015;56(9):1429\u201333.","journal-title":"J Nucl Med"},{"key":"2197_CR74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s12149-016-1081-z","volume":"30","author":"W Fujita","year":"2016","unstructured":"Fujita W, et al. Prediction of all-cause death using 11 C-hydroxyephedrine positron emission tomography in Japanese patients with left ventricular dysfunction. Ann Nucl Med. 2016;30:461\u20137.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"2197_CR75","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2967\/jnumed.114.140137","volume":"55","author":"AJ Sinusas","year":"2014","unstructured":"Sinusas AJ, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55(9):1445\u201351.","journal-title":"J Nucl Med"},{"key":"2197_CR76","unstructured":"Rischpler C, Schlitter A, Herz M, Yousefi B, Von Werder A, Tauber R, et al. First experience using LMI1195 PET in patients with the suspicion of pheochromocytoma or paraganglioma.\u00a0J Nucl Med. 2018;59(supplement 1):51.\u00a0"},{"issue":"11S","key":"2197_CR77","doi-asserted-by":"publisher","first-page":"A1482","DOI":"10.1016\/S0735-1097(18)32023-0","volume":"71","author":"J Zelt","year":"2018","unstructured":"Zelt J, et al. Fluorine-18 LMI1195 positron emission tomography provides accurate measure of cardiac sympathetic innervation compared to carbon-11 hydroxyephedrine. J Am Coll Cardiol. 2018;71(11S):A1482\u2013A1482.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2197_CR78","first-page":"1425","volume":"14","author":"JG Zelt","year":"2021","unstructured":"Zelt JG, et al. Regional distribution of fluorine-18-flubrobenguane and carbon-11-hydroxyephedrine for cardiac PET imaging of sympathetic innervation. Cardiovasc Imaging. 2021;14(7):1425\u201336.","journal-title":"Cardiovasc Imaging"},{"key":"2197_CR79","unstructured":"Mair B, Al Haddad R, Zelt J, Dinelle K, Quigley S, Beanlands R, et al. Assessing the pharmacokinetics and metabolism of [18F]LMI1195 in clinical imaging populations.\u00a0J Nucl Med.\u00a02020;61(supplement 1):1595. Society of Nuclear Medicine."},{"issue":"1","key":"2197_CR80","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2967\/jnumed.117.193169","volume":"59","author":"N Pandit-Taskar","year":"2018","unstructured":"Pandit-Taskar N, et al. Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET\/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147\u201353.","journal-title":"J Nucl Med"},{"key":"2197_CR81","unstructured":"Raffel D, Jung YW, Murthy V, Gu G, Rothley J, Koeppe R,\u00a0et al. First-in-human studies of 18F-hydroxyphenethylguanidines: PET radiotracers for quantifying cardiac sympathetic nerve density. J Nucl Med.\u00a02016;61(supplement 2):232.\u00a0"},{"issue":"12","key":"2197_CR82","first-page":"e007965","volume":"11","author":"DM Raffel","year":"2018","unstructured":"Raffel DM, et al. First-in-human studies of [18F] fluorohydroxyphenethylguanidines: positron emission tomography radiotracers for quantifying regional cardiac sympathetic nerve density. Circulation: Cardiovasc Imaging. 2018;11(12):e007965.","journal-title":"Circulation: Cardiovasc Imaging"},{"issue":"2","key":"2197_CR83","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00259-021-05517-7","volume":"49","author":"DM Raffel","year":"2022","unstructured":"Raffel DM, et al. Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients. Eur J Nucl Med Mol Imaging. 2022;49(2):619\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2197_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202302","volume":"13","author":"IA Burger","year":"2018","unstructured":"Burger IA, et al. Age-and sex-dependent changes in sympathetic activity of the left ventricular apex assessed by 18F-DOPA PET imaging. PLoS ONE. 2018;13(8): e0202302.","journal-title":"PLoS ONE"},{"issue":"3","key":"2197_CR85","doi-asserted-by":"publisher","first-page":"489","DOI":"10.31083\/j.jin.2020.03.196","volume":"19","author":"J Kuten","year":"2020","unstructured":"Kuten J, et al. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson\u2019s disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: proof-of-concept study. J Integr Neurosci. 2020;19(3):489\u201394.","journal-title":"J Integr Neurosci"},{"issue":"3","key":"2197_CR86","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s12350-020-02474-w","volume":"29","author":"H Goyal","year":"2022","unstructured":"Goyal H, et al. Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET\/CT in patients with autonomic dysfunction: feasibility study in IPD patients. J Nucl Cardiol. 2022;29(3):1280\u201390.","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"2197_CR87","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10286-022-00885-y","volume":"32","author":"DS Goldstein","year":"2022","unstructured":"Goldstein DS, Holmes C. Is 18F-DOPA a valid cardiac sympathetic neuroimaging agent? Clin Auton Res. 2022;32(6):445\u201353.","journal-title":"Clin Auton Res"},{"issue":"6","key":"2197_CR88","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10286-023-00987-1","volume":"33","author":"A Lenka","year":"2023","unstructured":"Lenka A, et al. Cardiac 18F-dopamine positron emission tomography predicts the type of phenoconversion of pure autonomic failure. Clin Auton Res. 2023;33(6):737\u201347.","journal-title":"Clin Auton Res"},{"key":"2197_CR89","doi-asserted-by":"crossref","unstructured":"Goldstein DS, et al. Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J Clin Investig. 2024;134(1):e172460.","DOI":"10.1172\/JCI172460"},{"issue":"Supplement 4","key":"2197_CR90","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.2967\/jnumed.115.157503","volume":"56","author":"AC Dimitriu-Leen","year":"2015","unstructured":"Dimitriu-Leen AC, Scholte AJ, Jacobson AF. 123I-MIBG SPECT for evaluation of patients with heart failure. J Nucl Med. 2015;56(Supplement 4):25S-30S.","journal-title":"J Nucl Med"},{"issue":"5","key":"2197_CR91","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/01.CIR.81.5.1606","volume":"81","author":"DS Goldstein","year":"1990","unstructured":"Goldstein DS, et al. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation. 1990;81(5):1606\u201321.","journal-title":"Circulation"},{"issue":"10","key":"2197_CR92","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM199703063361004","volume":"336","author":"DS Goldstein","year":"1997","unstructured":"Goldstein DS, et al. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med. 1997;336(10):696\u2013702.","journal-title":"N Engl J Med"},{"key":"2197_CR93","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.10.003","volume":"52","author":"DS Goldstein","year":"2018","unstructured":"Goldstein DS, et al. Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord. 2018;52:90\u20133.","journal-title":"Parkinsonism Relat Disord"},{"key":"2197_CR94","unstructured":"Rischpler C, Herz M, Yousefi B, Von Werder A, Tauber R, Robinson S,\u00a0et al. Regional myocardial tracer uptake of LMI1195 in heart-healthy subjects.\u00a0J Nucl Med. 2018;59(supplement 1):1546.\u00a0"},{"issue":"5","key":"2197_CR95","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.nucmedbio.2013.03.007","volume":"40","author":"JT Thackeray","year":"2013","unstructured":"Thackeray JT, et al. Test\u2013retest repeatability of quantitative cardiac 11C-meta-hydroxyephedrine measurements in rats by small animal positron emission tomography. Nucl Med Biol. 2013;40(5):676\u201381.","journal-title":"Nucl Med Biol"},{"key":"2197_CR96","first-page":"1437","volume":"14","author":"AJ Sinusas","year":"2021","unstructured":"Sinusas AJ, Liu C. Multi-tracer positron emission tomography quantification of sympathetic innervation: Tracer similarity but not equivalence. Am College CardiolFoundation Washington DC. 2021;14:1437\u20139.","journal-title":"Am College CardiolFoundation Washington DC"},{"issue":"5","key":"2197_CR97","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s12350-023-03338-9","volume":"30","author":"BA Mair","year":"2023","unstructured":"Mair BA, et al. Pharmacological and metabolic parameters of [18F] flubrobenguane in clinical imaging populations. J Nucl Cardiol. 2023;30(5):2089\u201395.","journal-title":"J Nucl Cardiol"},{"issue":"9","key":"2197_CR98","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1021\/jm061398y","volume":"50","author":"DM Raffel","year":"2007","unstructured":"Raffel DM, et al. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem. 2007;50(9):2078\u201388.","journal-title":"J Med Chem"},{"issue":"1","key":"2197_CR99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0969-8051(94)90135-X","volume":"21","author":"PK Garg","year":"1994","unstructured":"Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para-and meta-[18F] fluorobenzylguanidine. Nucl Med Biol. 1994;21(1):97\u2013103.","journal-title":"Nucl Med Biol"},{"issue":"11","key":"2197_CR100","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1021\/acschemneuro.5b00202","volume":"6","author":"B Hu","year":"2015","unstructured":"Hu B, et al. A practical, automated synthesis of meta-[18F] fluorobenzylguanidine for clinical use. ACS Chem Neurosci. 2015;6(11):1870\u20139.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"2197_CR101","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s00259-022-06046-7","volume":"50","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, et al. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients. Eur J Nucl Med Mol Imaging. 2023;50(4):1134\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2197_CR102","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S0006-2952(01)00787-0","volume":"62","author":"RE Yee","year":"2001","unstructured":"Yee RE, et al. Blood-brain barrier and neuronal membrane transport of 6-[18F] fluoro-L-DOPA. Biochem Pharmacol. 2001;62(10):1409\u201315.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"2197_CR103","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12350-022-03150-x","volume":"30","author":"T Thanigainathan","year":"2023","unstructured":"Thanigainathan T, et al. Imaging of cardiac sympathetic dysfunction with 18F-FDOPA PET\/CT in patients with heart failure: a pilot study. J Nucl Cardiol. 2023;30(3):1147\u201357.","journal-title":"J Nucl Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02197-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:02:27Z","timestamp":1772096547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02197-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"10 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"61"}}